Endiatx is developing PillBot, a 13×30 mm swallowable robotic capsule equipped with sensors, wireless connectivity, micropropellers for intraluminal maneuvering, and a high‑resolution camera that streams video (reported at 2.3 megapixels per second) to clinicians in real time. The capsule exits the body naturally after the procedure; the company states the device is safe and its CEO publicly ingested multiple units during development. Endiatx has begun clinical trials and raised $7 million to advance the program. Management plans to start pivotal testing at a leading U.S. gastroenterology center in Q3 or Q4 and is pursuing FDA approval. The company intends to improve PillBot’s video quality fourfold and to transition device control from physician‑driven operation to full AI autonomy. Endiatx also intends to monetize the clinical data PillBot collects and ultimately offer the product over the counter at about $50, targeting a U.S. launch by early 2026.

Total raised

$7M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2024